z-logo
open-access-imgOpen Access
Heart Failure
Author(s) -
David A. Kass
Publication year - 2012
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.112.124909
Subject(s) - decompensation , medicine , heart failure , maladaptation , psychiatry
The pathologically hypertrophied and failing heart is a battlefield in a war that would make even George Lucas proud. On the one side, you have hemodynamic, neurohormonal, morphologic, and cellular/molecular dark forces urging the ventricle towards decompensation and ultimate demise. On the other, Jedi signaling cascades valiantly try to stave off the impending disaster. Alas, unlike the movies, the dark side often wins, and we need better-equipped counter forces to change this. Current heart failure therapies are fairly defensive; blocking neuro-humoral stimuli and hemodynamic overload. However, adaptive/offensive strategies are advancing, including those aimed at enhancing metabolism, vascular supply, and cell regeneration, and those activating molecular signaling to counter maladaptation. (SELECT FULL TEXT TO CONTINUE)

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom